MYFORTIC 360 MG Israel - engelsk - Ministry of Health

myfortic 360 mg

novartis israel ltd - mycophenolic acid - gastro resistant tablets - mycophenolic acid 360 mg - mycophenolic acid - myfortic is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.

ZOFRAN TABLETS 8 MG Israel - engelsk - Ministry of Health

zofran tablets 8 mg

novartis israel ltd - ondansetron as hydrochloride dihydrate - tablets - ondansetron as hydrochloride dihydrate 8 mg - ondansetron - ondansetron - adults:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy.

ZOFRAN TABLETS 4 MG Israel - engelsk - Ministry of Health

zofran tablets 4 mg

novartis israel ltd - ondansetron as hydrochloride dihydrate - tablets - ondansetron as hydrochloride dihydrate 4 mg - ondansetron - ondansetron - adults:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy.

SANDOSTATIN  0.1 MGML Israel - engelsk - Ministry of Health

sandostatin 0.1 mgml

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

SANDOSTATIN  0.05 MGML Israel - engelsk - Ministry of Health

sandostatin 0.05 mgml

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.05 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

SANDOSTATIN 0.5 MG1ML Israel - engelsk - Ministry of Health

sandostatin 0.5 mg1ml

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.5 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome. vipomas . glucagonomas . gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

VIGAMOX Israel - engelsk - Ministry of Health

vigamox

novartis israel ltd - moxifloxacin as hydrochloride - ophthalmic solution - moxifloxacin as hydrochloride 0.5 % - moxifloxacin - moxifloxacin - for the treatment of bacterial conjunctivitis caused by susceptible strains or organisms.

PATANOL Israel - engelsk - Ministry of Health

patanol

novartis israel ltd - olopatadine as hydrochloride - eye drops - olopatadine as hydrochloride 1 mg/ml - olopatadine - olopatadine - for the temporary prevention of itching of the eye due to allergic conjunctivitis.

ATRIANCE 5 MGML Israel - engelsk - Ministry of Health

atriance 5 mgml

novartis israel ltd - nelarabine - solution for infusion - nelarabine 5 mg/ml - purine analogues - atriance 5 mg/ml is indicated for the treatment of patients with t-cell acute lymphoblastic leukaemia (t-all) and t-cell lymphoblastic lymphoma (t-lbl) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

TYKERB Israel - engelsk - Ministry of Health

tykerb

novartis israel ltd - lapatinib as ditosylate monohydrate - film coated tablets - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting .• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.